An N-ethyl-n-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess

Endocrinology

Volumn 155, Issue 3, 2014, Pages 908-922

  Bentley, Liz ^a   Esapa, Christopher T ^a,c   Nesbit, M Andrew ^c   Head, Rosie A ^a,c   Evans, Holly ^d   Lath, Darren ^d   Scudamore, Cheryl L ^b   Hough, Tertius A ^b   Podrini, Christine ^e   Hannan, Fadil M ^c   Fraser, William D ^f   Croucher, Peter I ^g   Brown, Matthew A ^h   Brown, Steve D M ^a   Cox, Roger D ^a   Thakker, Rajesh V ^c  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b Medical Research Council Harwell Institute   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; ETHYLNITROSOUREA; FRUCTOSAMINE; GLUCOCORTICOID; LUCIFERASE; MINERAL; OSTEOCALCIN; PARATHYROID HORMONE;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASE PAIRING; BONE DENSITY; BONE MINERALIZATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CUSHING SYNDROME; ENZYME ACTIVITY; EXPERIMENTAL OBESITY; FEMALE; GAIN OF FUNCTION MUTATION; HAIR LOSS; HYPERCALCEMIA; HYPERCALCIURIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY CONCENTRATING CAPACITY; MALE; MOUSE; MUSCLE ATROPHY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOMETRY; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROMOTER REGION; SKIN DISEASE; WILD TYPE;

ANIMALS; BODY COMPOSITION; BONE AND BONES; CALCIUM; CELL LINE; CHROMOSOME MAPPING; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; CUSHING SYNDROME; DISEASE MODELS, ANIMAL; ETHYLNITROSOUREA; FEMALE; GLUCOCORTICOIDS; LIPID METABOLISM; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MUTATION; OSTEOBLASTS; OSTEOPOROSIS; PROMOTER REGIONS, GENETIC;

EID: 84896890994     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1247     Document Type: Article

References (59)

1. Carroll TB, Findling JW. The diagnosis of Cushing's syndrome. Rev Endocr Metab Disord. 2010;11:147-153.
2. Bertagna X, Guignat L, Groussin L, Bertherat J. Cushing's disease. Best Pract Res Clin Endocrinol Metab. 2009;23:607-623.
3. Georgitsi M, Raitila A, Karhu A, et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci USA. 2007;104:4101-4105. (Pubitemid 47181585)
4. Stratakis CA, Tichomirowa MA, Boikos S, et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet. 2010;78:457-463.
5. Rix M, Hertel NT, Nielsen FC, et al. Cushing's disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur J Endocrinol. 2004;151:709-715. (Pubitemid 40090010)
6. Matsuzaki LN, Canto-Costa MH, Hauache OM. Cushing's disease as the first clinical manifestation of multiple endocrine neoplasia type 1 (MEN1) associated with an R460X mutation of the MEN1 gene. Clin Endocrinol (Oxf). 2004;60:142-143. (Pubitemid 38183510)
7. Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet. 1998;62:232-244. (Pubitemid 28110764)
8. Gaitan D, Loosen PT, Orth DN. Two patients with Cushing's disease in a kindred with multiple endocrine neoplasia type I. J Clin Endocrinol Metab. 1993;76:1580-1582. (Pubitemid 23164381)
9. Casey M, Vaughan CJ, He J, et al. Mutations in the protein kinase AR1α regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest. 2000;106:R31-R38.
10. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat Genet. 2000;26:89-92.
11. Groussin L, Jullian E, Perlemoine K, et al. Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab. 2002;87:4324-4329.
12. Bailey MA, Mullins JJ, Kenyon CJ. Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome. Hypertension. 2009;54:890-896.
13. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology. 1992;130:3378-3386.
14. Sarac MS, Zieske AW, Lindberg I. The lethal form of Cushing's in 7B2 null mice is caused by multiple metabolic and hormonal abnormalities. Endocrinology. 2002;143:2324-2332. (Pubitemid 34525081)
15. Sahut-Barnola I, de Joussineau C, Val P, et al. Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice. PLoS Genet. 2010;6: e1000980.
16. Harris C, Roohk DJ, Fitch M, Boudignon BM, Halloran BP, Hellerstein MK. Large increases in adipose triacylglycerol flux in Cushingoid CRH-Tg mice are explained by futile cycling. Am J Physiol Endocrinol Metab. 2013;304:E282-E293.
17. Acevedo-Arozena A, Wells S, Potter P, Kelly M, Cox RD, Brown SD. ENU mutagenesis, a way forward to understand gene function. Annu Rev Genomics Hum Genet. 2008;9:49-69.
18. Hough TA, Bogani D, Cheeseman MT, et al. Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification. Proc Natl Acad Sci USA. 2004;101:13566-13571. (Pubitemid 39238443)
19. Hough TA, Nolan PM, Tsipouri V, et al. Novel phenotypes identified by plasma biochemical screening in the mouse. Mamm Genome. 2002;13:595-602. (Pubitemid 35217512)
20. Stechman MJ, Ahmad BN, Loh NY, et al. Establishing normal plasma and 24-hour urinary biochemistry ranges in C3H, BALB/c and C57BL/6J mice following acclimatization in metabolic cages. Lab Anim. 2010;44:218-225.
21. Yao M, Denver RJ. Regulation of vertebrate corticotropin-releasing factor genes. Gen Comp Endocrinol. 2007;153:200-216. (Pubitemid 47102329)
22. King BR, Nicholson RC. Advances in understanding corticotropin-releasing hormone gene expression. Front Biosci. 2007;12:581-590. (Pubitemid 46852808)
23. King BR, Smith R, Nicholson RC. Novel glucocorticoid and cAMP interactions on the CRH gene promoter. Mol Cell Endocrinol. 2002; 194:19-28. (Pubitemid 35291916)
24. Budziszewska B, Jaworska-Feil L, Tetich M, et al. Regulation of the human corticotropin-releasing-hormone gene promoter activity by antidepressant drugs in Neuro-2A and AtT-20 cells. Neuropsychopharmacology. 2004;29:785-794. (Pubitemid 38402486)
25. Koh JM, Kim JY, Chung YE, et al. Increased urinary albumin excretion in Cushing's syndrome: remission after correction of hypercortisolaemia. Clin Endocrinol (Oxf). 2000;52:349-353. (Pubitemid 30169691)
26. Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab. 1998;83:801-806. (Pubitemid 28496450)
27. Godschalk MF, Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res. 1988; 3:113-115.
28. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39:81-93.
29. Hofbauer LC, Rauner M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol. 2009;23:1525-1531.
30. Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab. 2011; 22:499-506.
31. Morton NM, Seckl JR. 11β-Hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res. 2008;36:146-164.
32. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol. 2008;197:1-10. (Pubitemid 351566920)
33. Bahn R, Furth J, Anderson E, Gadsden E. Morphologic and functional changes associated with transplantable ACTH producing pituitary tumors of mice. Am J Pathol. 1957;33:1075-1097.
34. Helseth A, Haug E, Nesland JM, Siegal GP, Fodstad O, Bautch VL. Endocrine and metabolic characteristics of polyoma large T transgenic mice that develop ACTH-producing pituitary tumors. J Neurosurg. 1995;82:879-885.
35. Helseth A, Siegal GP, Haug E, Bautch VL. Transgenic mice that develop pituitary tumors. A model for Cushing's disease. Am J Pathol. 1992;140:1071-1080.
36. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev. 2005;10:7-13. (Pubitemid 40895311)
37. Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012;350:151-162.
38. Nussdorfer GG, Neri G, Belloni AS, Mazzocchi G, Rebuffat P, Robba C. Effects of ACTH on the zona glomerulosa of sodium-loaded timolol maleate-treated rats: stereology and plasma hormone concentrations. Acta Endocrinol (Copenh). 1982;99:256-262. (Pubitemid 12212757)
39. Dedic N, Touma C, Romanowski CP, et al. Assessing behavioural effects of chronic HPA axis activation using conditional CRH-overexpressing mice. Cell Mol Neurobiol. 2012;32:815-828.
40. Seale JV, Wood SA, Atkinson HC, et al. Gonadectomy reverses the sexually diergic patterns of circadian and stress-induced hypothalamic-pituitary-adrenal axis activity in male and female rats. J Neuroendocrinol. 2004;16:516-524. (Pubitemid 38878283)
41. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15:993-1000. (Pubitemid 30350061)
42. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319-1328. (Pubitemid 47389469)
43. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010;6:82-88.
44. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011;365:62-70.
45. Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res. 1989;4:137-141. (Pubitemid 19121785)
46. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282. (Pubitemid 28335186)
47. Au WY. Cortisol stimulation of parathyroid hormone secretion by rat parathyroid glands in organ culture. Science. 1976;193:1015-1017.
48. Fucik RF, Kukreja SC, Hargis GK, Bowser EN, Henderson WJ, Williams GA. Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab. 1975;40:152-155.
49. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab. 2006;17:144-149.
50. Jee WS, Yao W. Overview: animal models of osteopenia and osteoporosis. J Musculoskelet Neuronal Interact. 2001;1:193-207.
51. Weinstein RS, Chen JR, Powers CC, Stewart SA, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109:1041-1048. (Pubitemid 34408579)
52. Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology. 2010; 151:2641-2649.
53. Ovcharenko I, Nobrega MA, Loots GG, Stubbs L. ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res. 2004;32:W280-W286. (Pubitemid 38997344)
54. Schug J. Using TESS to predict transcription factor binding sites in DNA sequence. Curr Protoc Bioinformatics. 2008;Chapter 2:Unit 2.6.
55. Gaunt SJ, Paul YL. Origins of Cdx1 regulatory elements suggest roles in vertebrate evolution. Int J Dev Biol. 2011;55:93-98.
56. Houle M, Sylvestre JR, Lohnes D. Retinoic acid regulates a subset of Cdx1 function in vivo. Development. 2003;130:6555-6567. (Pubitemid 38088855)
57. van den Akker E, Forlani S, Chawengsaksophak K, et al. Cdx1 and Cdx2 have overlapping functions in anteroposterior patterning and posterior axis elongation. Development. 2002;129:2181-2193. (Pubitemid 34874231)
58. Subramanian V, Meyer BI, Gruss P. Disruption of the murine homeobox gene Cdx1 affects axial skeletal identities by altering the mesodermal expression domains of Hox genes. Cell. 1995;83:641-653.
59. Flicek P, Amode MR, Barrell D, et al. Ensembl 2012. Nucleic Acids Res. 2012;40:D84-D90.